Besides conventional markers to predict the response to ICIs, such as PD-L1 expression and tumor mutational burden, pretreatment serum miRNAs have also found use as a non-invasive diagnostic marker to select patients most likely to benefit from immune checkpoint blockade [379,380]. Here, CD274 is linked to neoplasm.